StockNews.com Initiates Coverage on Fresenius Medical Care (NYSE:FMS)

Research analysts at StockNews.com began coverage on shares of Fresenius Medical Care (NYSE:FMS) in a note issued to investors on Sunday. The firm set a “strong-buy” rating on the stock.

Separately, Truist Financial dropped their price objective on shares of Fresenius Medical Care from $24.00 to $22.00 and set a “hold” rating on the stock in a research note on Wednesday, July 31st. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, one has issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, Fresenius Medical Care currently has an average rating of “Hold” and an average price target of $22.00.

Fresenius Medical Care Stock Up 0.1 %

Fresenius Medical Care stock opened at $20.27 on Friday. The company has a market capitalization of $11.89 billion, a P/E ratio of 22.77, a PEG ratio of 1.09 and a beta of 0.90. The company has a debt-to-equity ratio of 0.45, a quick ratio of 1.09 and a current ratio of 1.46. Fresenius Medical Care has a fifty-two week low of $16.37 and a fifty-two week high of $22.76. The stock has a 50-day simple moving average of $19.57 and a 200-day simple moving average of $19.92.

Fresenius Medical Care (NYSE:FMS) last posted its quarterly earnings data on Tuesday, July 30th. The company reported $0.38 earnings per share for the quarter, meeting the consensus estimate of $0.38. The business had revenue of $5.13 billion during the quarter, compared to the consensus estimate of $5.28 billion. Fresenius Medical Care had a return on equity of 5.48% and a net margin of 2.72%. Equities research analysts expect that Fresenius Medical Care will post 1.51 earnings per share for the current year.

Hedge Funds Weigh In On Fresenius Medical Care

Several institutional investors have recently bought and sold shares of the company. Kimelman & Baird LLC purchased a new stake in shares of Fresenius Medical Care in the second quarter valued at about $186,000. Creative Planning boosted its holdings in Fresenius Medical Care by 18.9% in the 2nd quarter. Creative Planning now owns 40,140 shares of the company’s stock valued at $766,000 after purchasing an additional 6,373 shares in the last quarter. AQR Capital Management LLC acquired a new position in Fresenius Medical Care during the 2nd quarter worth approximately $197,000. Marshall Wace LLP raised its stake in shares of Fresenius Medical Care by 8.5% during the 2nd quarter. Marshall Wace LLP now owns 15,363 shares of the company’s stock worth $293,000 after buying an additional 1,207 shares in the last quarter. Finally, XTX Topco Ltd lifted its holdings in shares of Fresenius Medical Care by 82.1% in the 2nd quarter. XTX Topco Ltd now owns 23,282 shares of the company’s stock valued at $444,000 after buying an additional 10,497 shares during the period. 8.25% of the stock is owned by institutional investors and hedge funds.

Fresenius Medical Care Company Profile

Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure.